title: Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.
abstract: OBJECTIVE
  Using data from the CHAMPION percutaneous coronary intervention (PCI), we determined the relationship between clopidogrel started at least 5 days before PCI (maintenance of clopidogrel) and PCI-related enzymatic infarct size.
  
  
  BACKGROUND
  Clopidogrel is recommended in patients with acute coronary syndrome (ACS) managed with PCI, but its effect on PCI-related myonecrosis in contemporary patients has not been quantified.
  
  
  METHODS
  Patients with ACS (with or without ST-segment elevation) who underwent PCI and had at least three creatine kinase-MB (CK-MB) samples after PCI were included. Enzymatic infarct size was defined as the peak CK-MB concentration indexed by its upper limit of normal. Associations between maintenance clopidogrel and enzymatic infarct size were explored using multivariable linear regression (with and without missing data imputation) and propensity score analysis using inverse probability weighting.
  
  
  RESULTS
  Of 8877 patients randomized, 6327 (71.3%) were included (median age 61 years, 73% male, 13% ACS with ST-segment elevation). Of these 6327 patients, 2015 (31.8%) were on maintenance clopidogrel. After multivariable adjustment, maintenance clopidogrel was associated with a reduction in enzymatic infarct size {β=-0.63; 47% decrease in peak CK-MB [95% confidence interval (CI) 35, 56%]}. Multivariable linear regression with multiple imputations and inverse probability weighting propensity score analysis yielded similar results, with maintenance clopidogrel associated with 44% (95% CI 33, 53%) and 29% (95% CI 24, 33%) infarct size reductions.
  
  
  CONCLUSIONS
  In this subgroup analysis of modern ACS patients, clopidogrel maintenance was independently associated with smaller enzymatic infarct size after PCI. These results are consistent with previous observations suggesting a benefit of clopidogrel on the procedural outcome and quantify this benefit.
authors: Department of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA. sergio.leonardi@dm.duke.edu
authors: Sergio
authors: S
authors: Leonardi
authors: Amanda
authors: A
authors: Stebbins
authors: Renato D
authors: RD
authors: Lopes
authors: Yuliya
authors: Y
authors: Lokhnygina
authors: Meredith
authors: M
authors: Todd
authors: Deepak L
authors: DL
authors: Bhatt
authors: Gregg W
authors: GW
authors: Stone
authors: A Michael
authors: AM
authors: Lincoff
authors: Harold L
authors: HL
authors: Dauerman
authors: C Michael
authors: CM
authors: Gibson
authors: Harvey D
authors: HD
authors: White
authors: Keyur H
authors: KH
authors: Parikh
authors: Luis
authors: L
authors: Gruberg
authors: Howard C
authors: HC
authors: Herrmann
authors: Brent T
authors: BT
authors: McLaurin
authors: Shaun G
authors: SG
authors: Goodman
authors: Kenneth W
authors: KW
authors: Mahaffey
mesh_terms: D054058:Acute Coronary Syndrome / Q000201:enzymology* / Q000628:therapy; D000368:Aged; D000077144:Clopidogrel; D052279:Creatine Kinase, MB Form / Q000097:blood / Q000187:drug effects*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000201:enzymology* / Q000628:therapy; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D012720:Severity of Illness Index; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D052279:Creatine Kinase, MB Form; D013988:Ticlopidine